Skip to main content
Premium Trial:

Request an Annual Quote

Lumera, Harvard Proteomics Institute Will Use NAPPA Tech to Probe 200 Kinase Proteins

NEW YORK (GenomeWeb News) — Results of an ongoing collaboration between Lumera and the Harvard Institute of Proteomics have enabled the partners to try to use Lumera’s ProteomicProcessor biosensor to develop new diagnostics.
 
Since January, Harvard has served as a beta site for Lumera's platform. Researchers there have been trying to enable the ProteomicProcessor to analyze data from, their nucleic acid programmable protein array technology, also known as NAPPA.
 
Joshua LaBaer, director of the HIP, said in a statement todaty that "we now have a solid foundation on which to begin our development efforts. Among our first areas of investigation will be probing a family of 200 kinase proteins for their interaction with and among drug families relevant to cancer research."

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.